Business Wire

CQN-H2SITE

29.2.2024 15:56:33 CET | Business Wire | Press release

Share
CORRECTING and REPLACING, H2SITE Has Commissioned a Membrane Separator Capable of Extracting 5 to 20% Hydrogen Blends at +99% Purity From the Gas Distribution Network

Fourth paragraph should read: "The palladium membrane separators technology employed by H2SITE enables us to produce high-purity hydrogen suitable for fuel cell applications from blends with very low hydrogen concentrations," according to Andrés Galnares, CEO of H2SITE. "We have achieved the separation of over 97% of hydrogen at very high purity in the original gas stream while ensuring that the natural gas we deliver complies with the specifications of existing users."

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229560766/en/

The updated release reads: 

H2SITE HAS COMMISSIONED A MEMBRANE SEPARATOR CAPABLE OF EXTRACTING 5 TO 20% HYDROGEN BLENDS AT +99% PURITY FROM THE GAS DISTRIBUTION NETWORK

  • Located in Zamudio (Bizkaia), the separation unit is installed on a natural gas distribution network and operates with hydrogen concentrations ranging from 5 to 20%
  • It’s the first installation using palladium-alloy membrane separators reaching 97% hydrogen recovery rate at +99% purity
  • H2SITE has built similar units operating at high pressure levels and is developing projects at large scale in Europe.

H2SITE has successfully validated the feasibility of separating hydrogen (H2) blends ranging from 5% to 20% H2 concentration in regional distribution system operator (DSO) Nortegas' gas network, within the framework of the H2SAREA project.

The injection of hydrogen into the natural gas network is a solution that allows to leverage on existing infrastructure to transport low-carbon, renewable and pure hydrogen, provided that proper separation of this hydrogen can be carried out at the point of consumption at a limited cost.

The several million kilometers of established natural gas transport and distribution networks worldwide will be a necessary asset in the transition towards low-carbon energy sources. Through the H2SAREA project, H2SITE has demonstrated that the distribution infrastructure is compatible with the transport of blends of hydrogen and renewable natural gas, enabling the use of both pure fuels in sectors where each adds the most value thanks to our membrane separator technology.

"The palladium membrane separators technology employed by H2SITE enables us to produce high-purity hydrogen suitable for fuel cell applications from blends with very low hydrogen concentrations," according to Andrés Galnares, CEO of H2SITE. "We have achieved the separation of over 97% of hydrogen at very high purity in the original gas stream while ensuring that the natural gas we deliver complies with the specifications of existing users."

H2SITE is committed to making a significant contribution to the transition towards a cleaner and more sustainable energy matrix, aligning with Nortegas' vision for implementing advanced hydrogen solutions within the natural gas network.

Thanks to the technological validation in H2SAREA, we have taken a significant step forward in low-cost hydrogen transportation solutions.

About H2SITE

H2SITE was created in 2020 and has an exclusive technology of reactors and separators for the conversion of different feedstocks into hydrogen, among which are ammonia, methanol or synthetic gas, in addition to the separation of hydrogen from gaseous mixtures in low concentration for applications in salt caverns or geologic hydrogen.

(www.h2site.eu/)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240229560766/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release

Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ

Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release

The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College

Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release

As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi

ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release

Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye